DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

23 Drugs in Development

23 Drugs in Development

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

23DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: L59d69szn5, Rac-(ru(dmb)2(ip-3t))cl2, Tld1433, Tld-1433, 1471479-22-7, Unii-l59d69szn5

Molecular Formula

C₄₉H₃₈Cl₂N₈RuS₃

Molecular Weight

1007.1 g/mol

InChI Key

AVOZSOCUVHJHTQ-UHFFFAOYSA-L

FDA UNII

L59D69SZN5

Photodynamic Compound TLD-1433 is a non-toxic ruthenium-based coordination-complex and photosensitizer, with potential antineoplastic activity upon photodynamic therapy (PDT). Upon intravesical administration, light-activated photodynamic compound (PDC) TLD-1433 targets and binds to transferrin (Tf) and is subsequently taken up by Tf receptors which are located on tumor cells. Upon exposure to green light (525nm), TLD-1433 becomes activated locally and induces the generation of reactive oxygen species (ROS) and singlet oxygen. The release of free radicals may induce apoptosis and destroy the tumor cells. Cancer cells have many more Tf receptors than normal cells,

1 2D Structure

TLD-1433

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

4-methyl-2-(4-methylpyridin-2-yl)pyridine;ruthenium(2+);2-[5-(5-thiophen-2-ylthiophen-2-yl)thiophen-2-yl]-1H-imidazo[4,5-f][1,10]phenanthroline;dichloride

2.1.2 InChI

InChI=1S/C25H14N4S3.2C12H12N2.2ClH.Ru/c1-4-14-21(26-11-1)22-15(5-2-12-27-22)24-23(14)28-25(29-24)20-10-9-19(32-20)18-8-7-17(31-18)16-6-3-13-30-16;2*1-9-3-5-13-11(7-9)12-8-10(2)4-6-14-12;;;/h1-13H,(H,28,29);2*3-8H,1-2H3;2*1H;/q;;;;;+2/p-2

2.1.3 InChI Key

AVOZSOCUVHJHTQ-UHFFFAOYSA-L

2.1.4 Canonical SMILES

CC1=CC(=NC=C1)C2=NC=CC(=C2)C.CC1=CC(=NC=C1)C2=NC=CC(=C2)C.C1=CC2=C3C(=C4C=CC=NC4=C2N=C1)N=C(N3)C5=CC=C(S5)C6=CC=C(S6)C7=CC=CS7.[Cl-].[Cl-].[Ru+2]

2.2 Other Identifiers

2.2.1 UNII

L59D69SZN5

2.3 Synonyms

2.3.1 Depositor-Supplied Synonyms

1. L59d69szn5

2. Rac-(ru(dmb)2(ip-3t))cl2

3. Tld1433

4. Tld-1433

5. 1471479-22-7

6. Unii-l59d69szn5

7. Ruthenium(2+), Bis(4,4'-dimethyl-2,2'-bipyridine-.kappa.n1,.kappa.n1')(2-(2,2':5',2''-terthiophen)-5-yl-1h-imidazo(4,5-f)(1,10)phenanthroline-.kappa.n7,.kappa.n8)-, Chloride (1:2), (oc-6-21)-

8. Ruthenium(2+), Bis(4,4'-dimethyl-2,2'-bipyridine-kappan1,kappan1')(2-(2,2':5',2''-terthiophen)-5-yl-1h-imidazo(4,5-f)(1,10)phenanthroline-kappan7,kappan8)-, Chloride (1:2), (oc-6-21)-

2.4 Create Date

2020-01-23

3 Chemical and Physical Properties

Molecular Formula	C₄₉H₃₈Cl₂N₈RuS₃
Molecular Weight	1007.1 g/mol
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	12
Rotatable Bond Count	5
Exact Mass	1006.080202 g/mol
Monoisotopic Mass	1006.080202 g/mol
Topological Polar Surface Area	191 Å²
Heavy Atom Count	63
Formal Charge	0
Complexity	843
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	6